Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances on gene mutations of adult acute myeloid leukemia with normal karyotypes

( views:419, downloads:196 )

Author:: No author available

Journal Title:: Journal of Leukemia & Lymphoma

Issue:: 2

DOI:: 10.3760/cma.j.issn.1009-9921.2012.02.019

Key Word:: 白血病,髓样,急性;正常核型;突变;预后;Leukemia,myeloid,acute;Normal karyotypes;Mutation;Prognosis

Abstract： Acute myeloid leukemia (AML) is a disease with marked heterogeneity in both response to therapy and survival. Numerous genetic mutations which cannot be identified by cytogenetic detection have been found including gene mutations in Fms-liketyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), and CCAAT enhancer-binding protein-α (CEBPA). Furthermore, the panel of known molecular markers is continuously increasing,for example,considering the recently described isocitrate dehydrogenase (IDH1/2) and Wilms Tumour 1 gene (WT1) mutations. This review focuses on the structures and features of these gene mutations,as well as their influence on the prognosis of AML.

Reference

[1]孙明东,王国卿,李尊昌,等.伴NPM1基因突变的成年人急性髓系白血病临床研究[J].2011,(4).
[2]刘斌,陈燕.急性髓系白血病患者FLT3表达及TKD点突变的研究[J].2007,(1).
[3]Jorg, Basecke,Jarrett T, Whelan,Frank, Griesinger,etc.The MLL partial tandem duplication in acute myeloid leukaemia.[J].2006,135(4).
[4]Harada Y,Harada H.Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.[J].2009,220(1).
[5]Pollack JR,Frohling S,Dohner K,etc.Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.[J].2004,350(16).
[6]Stone RM.Prognostic factors in AML in relation to (ab)normal karyotype.[J].2009,22(4).
[7]Rau R,Brown P.Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.[J].2009,27(4).
[8]Konstanze, D?hner,Hartmut, D?hner.Molecular characterization of acute myeloid leukemia.[J].2008,93.
[9]Osato M.Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.[J].2004,23(24).
[10]Powell BL,Carter TH,Metzeler KH,etc.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.[J].2011,29(10).
[11]Paschka P,Fitzgibbon J,Owen C.The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.[J].2010,28(1).
[12]Philippe N,Pautas C,Geffroy S,etc.Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.[J].2010,28(23).
[13]Haferlach C,Haferlach T,Kern W,etc.Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.[J].2010,89(7).
[14]Su SM,Dang L,Jin S.IDH mutations in glioma and acute myeloid leukemia.[J].2010,16(9).
[15]Derek L, Stirewalt,Jerald P, Radich.The role of FLT3 in haematopoietic malignancies.[J].2003,3(9).
[16]Kanz L,Ganser A,Lubbert M,etc.Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.[J].2010,28(14).
[17]Pabst T,Narravula S,Radomska HS,etc.Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.[J].2001,27(3).
[18].Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.[J].2009,113(19).
[19]Kolitz JE,Paschka P,Perrotti D,etc.Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): a Cancer and Leukemia Group B Study.[J].2006,24(24).
[20]Delhommeau F,Dupont S,Della Valle V,etc.Mutation in TET2 in myeloid cancers.[J].2009,360(22).
[21]Maharry K,Caligiuri MA,Powell BL,etc.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.[J].2008,26(28).
[22]Haferlach T,Marcucci G,Dohner H.Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.[J].2011,29(5).
[23]Powell BL,Holland KB,Wetzler M,etc.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.[J].2010,28(14).
[24]Haferlach T,Bacher U,Schnittger S.Molecular genetics in acute myeloid leukemia.[J].2010,22(6).
[25]Benner A,Schlegelberger B,Bullinger L,etc.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.[J].2008,358(18).
[26]Haferlach C,Haferlach T,Kern W,etc.Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.[J].2008,111(5).
[27]Wermke M,Ehninger G,Schaich M,etc.Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.[J].2003,37(3).
[28]Kakkas I,Gale R,Lister TA,etc.Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.[J].2008,26(33).
[29]Falini B,Colombo E,Liso A,etc.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.[J].2005,352(3).
[30]Thiele J,Arber DA,Vardiman JW.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.[J].2009,114(5).
[31]Juan Du,Annika C. Russ,Sonja C. Luck.KIT mutations confer a distinct gene expression signature in core binding factor leukaemia[J].2010,148(6).
[32]Heuser M,Damm F,Morgan.Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.[J].2010,28(4).
[33]Weina, Chen,Dan, Jones,L Jeffrey, Medeiros,etc.Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.[J].2005,130(5).
[34]Suarez-Saiz F,Minden MD,Yang L,etc.A tumor suppressor and oncogene: the WT1 story.[J].2007,21(5).
[35]Paschka P,Schlenk RF,Gaidzik VI,etc.IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.[J].2010,28(22).
[36]Kayser S,Schlenk RF,Londono MC.Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.[J].2009,114(12).
[37]Santos FP,Cortes JE,Estey EE,etc.Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.[J].2011,117(10).
[38]Gaidzik VI,Nachbaur D,Schlenk RF,etc.RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.[J].2011,29(10).
[39]Ma Y,Reguera MJ,Longley BJ.Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.[J].2001,25(7).